Recent studies demonstrated the relative efficacy on CML cells of imatinib in combination with Jak2 inhibitor TG101348 (cytostatic effect), the CXCR4 antagonist BKT140, or the proteasome inhibitor carfilzomib (cytotoxic effect but 50% of cell death only) [86,87,88]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.